Observational study finds GLP-1 drugs associated with 37% increased alopecia risk — Evidence Review

A large study from the University of Pennsylvania Health System suggests that GLP-1 drugs like Ozempic and Mounjaro are associated with a slightly increased risk of hair loss in adults with type 2 diabetes. Related research generally supports this association, indicating that hair loss may be an underrecognized side effect of these medications as their use becomes more widespread; see the original study source for more details.

• Multiple systematic reviews and meta-analyses confirm a higher risk of alopecia with GLP-1 receptor agonists, particularly semaglutide and tirzepatide, compared to other diabetes drugs, with the effect likely related to rapid weight loss and possible nutritional deficiencies 1 3 4 5 6.
• Cross-sectional and retrospective studies highlight that hair loss can be psychologically distressing, tends to be non-scarring and reversible, and disproportionately affects certain groups (e.g., females, Mounjaro users), supporting the need for patient counseling and monitoring 2 7.
• While the new study strengthens the evidence for this association, mechanisms remain unclear, and prior research calls for further investigation into causality, risk factors, and whether hair loss resolves after treatment cessation 3 4 6.

Study Overview and Key Findings

As GLP-1 receptor agonists such as Ozempic and Mounjaro gain popularity for managing type 2 diabetes and obesity, attention is turning to their full side effect profile beyond glycemic control and weight loss. Hair loss has been reported anecdotally and in pharmacovigilance data, but robust head-to-head comparisons with other diabetes medications have been lacking. This large observational study addresses that gap by directly comparing the incidence of alopecia among GLP-1 users versus those on SGLT-2 or DPP-4 inhibitors, using electronic health records from a major health system.

Property	Value
Study Year	2026
Organization	University of Pennsylvania Health System
Journal Name	BMJ
Authors	Huilin Tang, Bingyu Zhang, Yiwen Lu, Dazheng Zhang, Ruishan Liu, Yuan Lu, George Cotsarelis, David A Asch, Yong Chen
Population	Adults with type 2 diabetes
Sample Size	n=12,004 GLP-1 users, n=15,221 SGLT-2 users, n=11,964 GLP-1 users, n=11,233 DPP-4 users
Methods	Observational Study
Outcome	Risk of alopecia associated with diabetes medications
Results	GLP-1 drugs linked to 37% higher alopecia risk than SGLT-2 inhibitors.

The study found that adults with type 2 diabetes starting GLP-1 receptor agonists had a higher risk of developing alopecia—particularly non-scarring types—than those starting SGLT-2 or DPP-4 inhibitors, even after accounting for age, sex, BMI, and comorbidities. The absolute risk was low (around 6.5–7 cases per 1,000 person-years), but the relative increase was notable (up to 68% higher compared to DPP-4 inhibitors). The researchers could not determine if this was a direct drug effect or secondary to rapid weight loss, nutritional changes, or other metabolic shifts.

Literature Review: Related Studies

To contextualize these findings, we searched the Consensus database, which includes over 200 million research papers. The following queries were used:

1. ozempic hair loss side effects
2. mounjaro alopecia risk comparison
3. GLP-1 drugs alopecia prevalence studies

Below, key themes from related studies are summarized.

Topic	Key Findings
How strong is the evidence that GLP-1 drugs increase hair loss risk?	- Multiple systematic reviews and meta-analyses report a significant, though low absolute, increase in alopecia risk among GLP-1RA users compared to placebo or other diabetes medications, with semaglutide and tirzepatide most implicated 3 4 5 6. - Observational and cross-sectional studies reinforce the association, noting higher prevalence with certain drugs 2 3 5 7.
What are the characteristics and potential mechanisms of hair loss with GLP-1 drugs?	- Hair loss is typically non-scarring (e.g., telogen effluvium), often reversible, and may be linked to rapid weight loss, metabolic stress, or nutritional deficiencies 1 2 3 4 6. - Some studies suggest possible direct effects on the hair follicle cycle, but causality is unconfirmed and human mechanistic data are lacking 4 6.
Who is most at risk and what are the clinical implications?	- Female patients and users of Mounjaro (tirzepatide) or semaglutide are disproportionately affected, with psychological distress and potential impact on treatment adherence reported 2 7. - Clinicians are advised to counsel patients on the risk, monitor for hair loss, and ensure adequate nutrition during treatment 1 2 6 7.
Are there long-term or potentially beneficial effects on hair?	- Rare reports suggest possible hair regrowth or improvement in some alopecia subtypes with GLP-1RA use, potentially linked to improved glycemic control, but evidence is limited and mechanisms are unclear 3. - The relationship between GLP-1RAs and hair outcomes may vary by individual, hair loss type, and metabolic context 3 7.

How strong is the evidence that GLP-1 drugs increase hair loss risk?

The new study's finding of a modestly elevated risk of alopecia among GLP-1 users aligns with several systematic reviews, meta-analyses, and observational studies. These analyses consistently report that GLP-1 receptor agonists, particularly semaglutide and tirzepatide, are associated with higher rates of hair loss compared to placebo or other diabetes drugs, although the absolute incidence remains low.

• Systematic reviews and meta-analyses consistently identify a weak to moderate association between GLP-1RA use and alopecia, with risk ratios ranging from 1.2 to 3.4 3 4 5 6.
• The effect is most pronounced with semaglutide and tirzepatide, corroborating the drugs most frequently cited in pharmacovigilance data 3 5 6.
• Observational studies and database analyses confirm these findings in real-world populations, noting increased odds ratios for hair loss diagnoses in GLP-1RA users 2 7.
• Despite consistent associations, causality remains unproven due to potential confounding factors, such as baseline metabolic status or weight loss 3 4 6.

What are the characteristics and potential mechanisms of hair loss with GLP-1 drugs?

The literature suggests that hair loss associated with GLP-1 drugs is predominantly non-scarring (e.g., telogen effluvium), tends to be reversible, and is likely multifactorial in origin. Rapid weight loss, metabolic stress, and nutritional deficiencies (e.g., iron, zinc, vitamin D) are frequently cited contributors. Some animal studies suggest that GLP-1 receptors are present in hair follicles, raising the possibility of a direct pharmacologic effect, though human data are inconclusive.

• Hair loss generally manifests as increased shedding several months after drug initiation, consistent with telogen effluvium 1 2 4 6.
• The phenomenon is often temporary and resolves with time, nutritional support, or cessation of rapid weight loss 2 6.
• Mechanistic hypotheses include both indirect effects (weight loss, nutrient deficiency) and possible direct modulation of the hair cycle by GLP-1 signaling 4 6.
• The distinction between scarring and non-scarring alopecia is important for prognosis, with most reported cases being non-scarring and thus potentially reversible 2 4.

Who is most at risk and what are the clinical implications?

Evidence indicates that certain populations—especially women and those using Mounjaro or semaglutide—may be at greater risk for experiencing hair loss while on GLP-1 therapy. Psychological distress and concerns about appearance can affect treatment adherence, highlighting the importance of patient education and monitoring.

• Female sex and use of tirzepatide (Mounjaro) are strong predictors of reported hair loss in GLP-1RA users 2 7.
• Hair loss can cause significant emotional or psychological impact, affecting quality of life and willingness to continue therapy 2.
• Clinical guidelines increasingly recommend that practitioners discuss the potential for hair loss with patients starting GLP-1RAs and monitor for this side effect 1 2 6 7.
• Ensuring adequate nutrition and addressing modifiable risk factors may help mitigate the risk or severity of hair loss 1 6.

Are there long-term or potentially beneficial effects on hair?

While the preponderance of evidence points to hair loss as an adverse event, a few studies note that, in some cases, GLP-1RA therapy may be associated with hair regrowth or stabilization, especially in those with pre-existing metabolic-related alopecia. However, these findings are rare, and the mechanisms are not well understood.

• A handful of case reports and small cohorts describe hair regrowth or improvement in scalp symptoms among GLP-1RA users, potentially linked to better glycemic control 3.
• These effects appear to be the exception rather than the rule and are not well characterized in larger studies 3.
• The type of hair loss (e.g., androgenetic, telogen effluvium, cicatricial) may influence the direction and magnitude of drug effects 3 7.
• Further research is needed to clarify whether certain subpopulations may benefit, rather than be harmed, in terms of hair health when treated with GLP-1RAs 3.

Future Research Questions

Although the evidence for a link between GLP-1 receptor agonists and hair loss is growing, key questions remain regarding causality, mechanisms, risk stratification, and management. Future studies are needed to clarify underlying biological pathways, identify at-risk populations, and develop preventive or supportive strategies for affected patients.

Research Question	Relevance
What is the mechanism underlying GLP-1RA-associated hair loss?	Clarifying whether hair loss is due to direct drug effects, metabolic changes, or nutritional deficiencies would aid in targeted prevention and management strategies 3 4 6.
Which patients are most susceptible to hair loss from GLP-1 therapy?	Identifying risk factors (e.g., sex, age, baseline hair health, drug type) can inform patient selection and counseling, potentially reducing distress and improving adherence 2 7.
Does hair loss resolve after GLP-1RA discontinuation?	Understanding the reversibility and timeline of hair loss is critical for patient reassurance and management, given that most cases appear non-scarring and potentially reversible 2 4 6.
How does nutritional status or supplementation impact hair loss risk in GLP-1RA users?	Since nutritional deficiencies may contribute to hair loss, research on dietary interventions or supplementation could help reduce risk in susceptible patients 1 3 6.
Are there differences in hair loss risk among different GLP-1 receptor agonists?	Determining whether specific agents (e.g., semaglutide, tirzepatide, liraglutide) carry different levels of risk can inform personalized prescribing and risk-benefit discussions 3 5 6 7.

Continued research in these areas will help clarify the risks, mechanisms, and optimal management strategies for hair loss associated with GLP-1 receptor agonist therapy, improving patient care as use of these medications continues to grow.